Currently, there are 244.92M common shares owned by the public and among those 238.24M shares have been available to trade.
The company’s stock has a 5-day price change of -18.85% and 51.15% over the past three months. LXRX shares are trading 29.41% year to date (YTD), with the 12-month market performance down to -14.66% lower. It has a 12-month low price of $0.92 and touched a high of $3.79 over the same period. LXRX has an average intraday trading volume of 4.73 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.93%, -11.94%, and 13.49% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) shares accounts for 74.32% of the company’s 244.92M shares outstanding.
It has a market capitalization of $484.96M and a beta (3y monthly) value of 1.27. The earnings-per-share (ttm) stands at -$0.79. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.01% over the week and 9.85% over the month.
Analysts forecast that Lexicon Pharmaceuticals Inc (LXRX) will achieve an EPS of -$0.2 for the current quarter, -$0.18 for the next quarter and -$0.66 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.2 while analysts give the company a high EPS estimate of -$0.19. Comparatively, EPS for the current quarter was -$0.17 a year ago. Earnings per share for the fiscal year are expected to increase by 10.13%, and 7.51% over the next financial year.
Looking at the support for the LXRX, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on March 07, 2023, with the firm’s price target at $3. Piper Sandler coverage for the Lexicon Pharmaceuticals Inc (LXRX) stock in a research note released on August 12, 2022 offered a Overweight rating with a price target of $10. JP Morgan was of a view on January 29, 2021 that the stock is Neutral, while Wedbush gave the stock Neutral rating on January 29, 2021, issuing a price target of $2- $8. Citigroup on their part issued Buy rating on December 08, 2020.
